A Cochrane systematic review asked whether medications reduce daytime sleepiness and related symptoms in people with idiopathic hypersomnia, a disorder of excessive daytime sleepiness without a known cause. The reviewers searched major databases in February 2021 for randomized studies comparing any medication with placebo, another medication, or a behavioral intervention.
The review included three trials with 112 participants total. Two company-sponsored trials compared modafinil with placebo in 102 participants, nearly all of whom had idiopathic hypersomnia without long sleep time. The third, much smaller trial tested clarithromycin in a mixed group and contributed only a subset of participants with idiopathic hypersomnia.
For the main outcome, self-reported sleepiness on the Epworth Sleepiness Scale improved by 5.08 points more with modafinil than placebo (95% CI 3.01 to 7.16; 2 studies, 101 participants; high-certainty evidence). The comparison was modafinil versus placebo, not versus another active treatment. Objective wakefulness on the Maintenance of Wakefulness Test also improved, by 4.74 minutes more than placebo (95% CI 2.46 to 7.01; 2 studies, 99 participants; high-certainty evidence).
Trust is limited by the small number of trials and participants, and by the narrow population: mostly people without long sleep times, so results may not generalize to everyone with idiopathic hypersomnia. The abstract reports low risk of bias but does not describe randomization or blinding details. Side effects were more frequent with modafinil, but the difference was not statistically significant (low-certainty evidence). Evidence for clarithromycin was insufficient. A useful question: would these results hold in people with long sleep times, who were largely excluded?
Review: PMID 34031871 · DOI 10.1002/14651858.CD012714.pub2
Написать Join — чтобы участвовать в обсуждении.